On March 23, 2021, Bayer announced that it is collaborating with NeoGenomics, Tempus, and Veracyte to sponsor genomic cancer testing for actionable alterations, including NTRK gene fusions. These programs are available to eligible patients at no cost. Bayer will cover the full cost of the test regardless of the results, patient’s insurance coverage, and resulting treatment decision.
Eligibility includes patients with RAI-refractory differentiated thyroid carcinoma and metastatic colorectal cancer with high microsatellite instability.
Enrollment for the the programs is available for a limited time, and these genomic testing programs include:
Visit each program's website for more information.
Posted 3/24/2021
Understanding both the benefits to be had from offering BsAb therapy to its community and the scope of this undertaking, Vanderbilt-Ingram Cancer Center took a novel approach with its APP-led BsAb step-up dosing clinic, which won the program a 2026 ACCC Innovator Award.
